Articles

Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.

Cannabidiol for Potentially Treating Psychosis: International Study Launched by University of Oxford

The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.

House and Senate Introduce Bill to Direct Veterans Affairs to Study Medical Cannabis to Treat Certain Conditions

Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.

Recent Studies from Medical Marijuana Inc. Test Cannabidiol for Treatment of Two Conditions

Starting July 1, 2023, Australia will allow the use of psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) for therapeutic use in a medical setting to treat mental health conditions.

Australia to Reschedule Psilocybin and MDMA for Therapeutic Use Starting in July 2023

On February 2nd, Americans for Safe Access (ASA) held an editorial/press briefing to present their 2022 State of the States report, which graded each US state and four territories on patient access to cannabis. ASA is the nation’s largest member-based organization promoting safe and legal access to cannabis for therapeutic use and research.

Americans for Safe Access Presents the 2022 State of the States Report: What’s New and What’s Next

A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.

Food and Drug Administration to Work with Congress on Creating Regulatory Framework for the Cannabidiol Market

As access to edible cannabis increases for adults across the United States, children are also becoming more exposed as well.

Child Welfare Concerns Increasing across the Country over Ingestion of Cannabis

Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.

Psilocybin and Bipolar Disorder: Careful Clinical Studies are Warranted, Survey Study Suggests

This 1 CME credit article evaluates evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder.

Continuing Medical Education (CME) Article from Psychiatric Times: Current Treatments for Cannabis Use Disorder

A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.

All News